1. Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck
- Author
-
James H. Doroshow, Christine Cripps, John Gyves, Susan G. Urba, Enrique Velez-Garcia, Brian Dallaire, Francisco Robert, Randall Carlson, Antonio Grillo-Lopez, and David B. Adams
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Urology ,Antineoplastic Agents ,Toxicology ,Drug Administration Schedule ,Carcinoma ,medicine ,Humans ,Pharmacology (medical) ,In patient ,Basal cell ,Head and neck ,Aged ,Pharmacology ,Brequinar sodium ,Chemotherapy ,business.industry ,Biphenyl Compounds ,Middle Aged ,medicine.disease ,Surgery ,Oncology ,Head and Neck Neoplasms ,Weekly dose ,Toxicity ,Carcinoma, Squamous Cell ,Female ,business - Abstract
A total of 19 patients with advanced squamous-cell carcinoma of the head and neck who had not previously been exposed to chemotherapy were treated with brequinar sodium as first-line chemotherapy. Brequinar was given intravenously at a median weekly dose of 1,200 mg/m2. The toxicity was moderate, with 7 patients (37%) experiencing grade 3 or 4 toxicity. In all, 16 patients who were evaluable for efficacy showed no objective response. We conclude that brequinar given at this dose and on this schedule has no significant activity in advanced squamous-cell carcinoma of the head and neck.
- Published
- 1992